Please try another search
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Daniel Kaufman | 65 | 1996 | Member of the Scientific Advisory Board |
Erik Nerpin | 62 | 2012 | Independent Vice Chairman |
Mark A. Atkinson | 62 | 1997 | Chairman of Scientific Advisory Board & Independent Director |
David Leslie | 74 | 1999 | Member of the Scientific Advisory Board |
Maria-Teresa Essen-Möller | 53 | 2009 | Independent Director |
Anders Essen-Möller | 82 | 1996 | Independent Chairman |
Ake Lernmark | 78 | 1996 | Member of the Scientific Advisory Board |
Torbjörn Bäckström | 75 | 2017 | Independent Director |
Karin M. Hehenberger | 51 | 2021 | Independent Director |
Karin Rosen | 56 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review